On August 4, 2026, Rhythm Pharmaceuticals reported second quarter 2026 financial results and business updates. Net product revenue from global sales of IMCIVREE reached $71.3 million, a 19% sequential increase driven by U.S. sales of $51.0 million following the March FDA approval for acquired hypothalamic obesity (HO). The company received more than 400 patient start forms from approximately 300 prescribers since approval. Rhythm reported a net loss attributable to common stockholders of $(50.4) million, or $(0.73) per share, compared to $(48.0) million in the prior year period. Cash and short-term investments stood at $330.9 million as of June 30, 2026. The company also announced preliminary Phase 2 data for investigational drug RM-718 in acquired HO patients, showing an 11.6% mean BMI reduction at 16 weeks with a favorable safety profile regarding hyperpigmentation. Rhythm operates as a commercial-stage biopharmaceutical company focused on treating rare neuroendocrine diseases.

Rhythm Pharmaceuticals announced interim six-month Phase 2 trial data for setmelanotide in patients with Prader-Willi syndrome (PWS). Results showed a 3.06% mean BMI reduction in the total group and a 3.11% reduction in adults. The trial also demonstrated preservation of lean mass and reductions in fat mass. Additionally, the company presented multiple data analyses at the ENDO 2026 meeting, including long-term efficacy of setmelanotide in acquired hypothalamic obesity, 1-year results for oral bivamelagon, and real-world effectiveness in patients with Bardet-Biedl syndrome. The company also updated its PWS epidemiology estimates for the U.S. and Europe. Rhythm Pharmaceuticals is a biotechnology company focused on developing treatments for rare genetic diseases that cause obesity.